"TAVR devices make the procedure more expensive that the conventional surgical approach"
Do you have any figures to back that up? I noticed later you talk about cost reductions through shorter stay etc, but I'm pretty sure if you take into account costs of the operating theatre and staff, bypass technicians and resources, post op ICU care and so on, costs of conventional open surgical aortic valve replacement are a lot more than transcatheter valve replacements, not to mention comfort.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-439
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.73 |
Change
-0.270(1.93%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.05 | $14.05 | $13.73 | $48.71K | 3.516K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.83 | 268 | 1 |
View Market Depth
| Last trade - 11.54am 08/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |